Technologies for HMO Production

Technologies for HMO Production

As a high-level company focusing on glycochemistry and glycobiology research for nearly 20 years, CD BioGlyco provides a variety of technologies for HMO production, including chemical methods, whole-cell biotransformation (fermentation), enzyme catalysis (isolated enzyme biotransformation) and chemoenzymatic methods.

Health Benefits of HMOs

According to many in vitro, in vivo, and clinical studies, the intake, and consumption of HMO can benefit the gastrointestinal tract, immune system, respiratory system, urinary system, central nervous system, motor system, circulatory system, and so on. Diversity in HMO production also has broad positive impacts on human health, providing improved nutrition for non-breastfed infants and sources of bioactive compounds. In conclusion, it has become very desirable to add HMO to infant formulas or other functional foods. Currently, many scientists are studying the mechanism and synthesis method of HMO, which makes it a promising additive for infant formula in the future.

Structural diversity of HMOs. Fig.1 Structural diversity of HMOs. (Grabarics, et al., 2017)

Technologies for HMO Production at CD BioGlyco

For HMO production, in addition to separation and purification, there are roughly three other methods:

  • Biocatalytic methods

Whole-cell biotransformation (fermentation), enzyme catalysis (isolated enzyme biotransformation)

Currently, biocatalytic methods are the methods with the highest HMO yields. The mass production of HMO is more targeted at the fermentation production of 2'-fucosyllactose and lactose-N-neotetraose, and then the products are applied to infant formula milk powder.

  • Chemoenzymatic methods

The chemoenzymatic methods of HMOs can not only reduce the toxic effect caused by chemical synthesis but are also not limited to the production of fewer types of simple oligosaccharides like simple biosynthesis.

  • Chemical methods

Due to its accompanying reagent toxicity and complex reaction conditions, chemical synthesis can initially provide some common precursors for chemical enzymatic methods, so that it can better exert its own advantages.

Based on these technologies, we are also continuously optimizing the control of details in all aspects, combining the advantages of good technologies and resources to complement each other, including shortening the fermentation time, simplifying the purification steps, increasing the yield, increasing the degree of polymerization of HMO, etc.

Through long-term experiments and research, our professional technical researchers are at the leading level in the world in the application and improvement of methods for HMO production. If you are interested in our related services, please feel free to contact us. CD BioGlyco is confident to become your irreplaceable production assistant in the HMO field.


  1. Grabarics, M.; et al. Analytical characterization of human milk oligosaccharides – potential applications in pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis. 2017, 146: 168-178.
  2. Pérez-Escalante, E.; et al. Human milk oligosaccharides as bioactive compounds in infant formula: recent advances and trends in synthetic methods. Critical Reviews in Food Science and Nutrition. 2022, 62(1): 181-214.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.